CA Patent

CA3140889A1 — Carbachol-brimonidine formulations to enhance anti-presbyopia effects

Assigned to Visus Therapeutics Inc · Expires 2020-12-17 · 5y expired

What this patent protects

Use of topical carbachol in combination with brimonidine to create optically beneficial miosis to temporarily treat presbyopia. A pharmaceutical formulation is used comprising a therapeutically effective amount of carbachol, or a pharmaceutically acceptable salt thereof, in combi…

USPTO Abstract

Use of topical carbachol in combination with brimonidine to create optically beneficial miosis to temporarily treat presbyopia. A pharmaceutical formulation is used comprising a therapeutically effective amount of carbachol, or a pharmaceutically acceptable salt thereof, in combination with brimonidine, or a pharmaceutically acceptable salt thereof, specifically combined with permeation enhancers and excipients to increase efficacy and reduce ocular surface toxicity and improve tolerability.

Drugs covered by this patent

Patent Metadata

Patent number
CA3140889A1
Jurisdiction
CA
Classification
—
Expires
2020-12-17
Drug substance claim
No
Drug product claim
No
Assignee
Visus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.